Congress doubles pharma tax break for rare-disease drugs—no price controls attached

What it does

This bill doubles the orphan drug tax credit from 25% to 50% for pharmaceutical companies developing drugs for rare diseases. The credit applies to qualified clinical testing expenses, allowing companies to deduct a larger percentage of their R&D costs against federal taxes, effective immediately upon enactment.

Why we flagged it

The bill's operative mechanism is a direct reduction in federal tax liability for pharmaceutical companies engaged in orphan drug development. It is a tax expenditure — a subsidy delivered through the tax code rather than direct appropriation — and benefits a specific industry sector.

What the text implies

• The bill does not condition the tax credit on drug affordability, price caps, or patient access — companies may claim the full credit while charging high prices for resulting treatments.
• Doubling the credit increases federal revenue loss (a cost to the general taxpayer) with no sunset or review mechanism; the benefit is permanent unless Congress acts again.
• The credit is available to all orphan drug developers regardless of profitability or market position, potentially subsidizing large pharmaceutical companies' R&D that they would conduct anyway.
• No requirement for transparency on how tax savings are deployed — companies may use freed capital for stock buybacks, executive compensation, or non-R&D purposes rather than accelerated drug development.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill may accelerate development of treatments for rare diseases (a public health benefit), but it does so by reducing federal tax revenue and providing a direct subsidy to pharmaceutical companies with no requirement that cost savings be passed to patients or that drug prices be capped. The public benefit is speculative and contingent on company behavior; the private tax benefit is immediate and certain.

Who stands to gain

• pharmaceutical companies developing orphan drugs
• biotech firms with rare-disease pipelines

Named in the bill

Internal Revenue Code Section 45C, orphan drug tax credit, pharmaceutical industry, rare disease treatment developers

Where it stands

19 cosponsors: 11 Republicans, 8 Democrats.

• Feb 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 18, 2025 — Referred to House Committee on Ways and Means · Congress.gov: “Referred to the House Committee on Ways and Means”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

16 lobbying clients named this bill on 25 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $8,546,396 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 95% of bills with at least one filing.

Josh Gottheimer, the sponsor, reported $1,000,800 in PAC receipts in the 2026 cycle.

• Astrazeneca Pharmaceuticals Lp — $2,350,000 on 2 filings
• Vertex Pharmaceuticals Incorporated — $2,310,000 on 2 filings
• Acadia Pharmaceuticals — $1,290,000 on 2 filings
• Alkermes, Inc. — $870,000 on 1 filing
• Travere Therapeutics — $400,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.